The Persistence of Silodosin Monotherapy and the Reasons for Withdrawal from Treatment of Previously Untreated Japanese Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia

The Persistence of Silodosin Monotherapy and the Reasons for Withdrawal from Treatment of Previously Untreated Japanese Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia

Objectives. The persistence of silodosin and the reasons for withdrawal from treatment of previously untreated Japanese patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) were evaluated in real-life clinical practice. Methods. A total of 81 previously un...

Full description

Bibliographic Details
Main Authors:	Yoshinori Tanaka, Yasushi Tanuma, Naoya Masumori
Format:	Article
Language:	English
Published:	Hindawi Limited 2017-01-01
Series:	Advances in Urology
Online Access:	http://dx.doi.org/10.1155/2017/4842025

Similar Items

Silodosin in the treatment of benign prostatic hyperplasia
by: Maxime Rossi, et al.
Published: (2010-10-01)

Investigation of the reasons for withdrawal from long-term treatment with mirabegron of treatment-naïve Japanese female patients with overactive bladder in the real-world clinical setting
by: Yoshinori Tanaka, et al.
Published: (2019-01-01)

Safety and efficacy of silodosin for the treatment of benign prostatic hyperplasia
by: Yoshida M, et al.
Published: (2011-06-01)

Silodosin for the treatment of clinical benign prostatic hyperplasia: safety, efficacy, and patient acceptability
by: Cho HJ, et al.
Published: (2014-09-01)

The Effectiveness of Silodosin for Nocturnal Polyuria in Elderly Men With Benign Prostatic Hyperplasia: A Multicenter Study
by: Young Won Kim, et al.
Published: (2015-09-01)

Investigation of ejaculatory disorder by silodosin in the treatment of prostatic hyperplasia
by: Sakata Koichi, et al.
Published: (2012-10-01)

Post-Marketing Surveillance of Silodosin in Patients with Benign Prostatic Hyperplasia and Poor Response to Existing Alpha-1 Blockers: The SPLASH Study
by: Hiroshi Takahashi, et al.
Published: (2019-01-01)

The predictive factors of α1-D/A adrenoceptor antagonist, naftopidil, dose increase therapy for male lower urinary tract symptoms caused by benign prostatic hyperplasia: INFORM study
by: Yasushi Tanuma, et al.
Published: (2017-01-01)

Naftopidil for the treatment of urinary symptoms in patients with benign prostatic hyperplasia
by: Masumori N
Published: (2011-06-01)

Silodosin 8 mg improves benign prostatic obstruction in Caucasian patients with lower urinary tract symptoms suggestive of benign prostatic enlargement: results from an explorative clinical study
by: Ferdinando Fusco, et al.
Published: (2018-03-01)

Efficacy and Safety of Silodosin and Dutasteride Combination Therapy in Acute Urinary Retention due to Benign Prostatic Hyperplasia: A Single-Arm Prospective Study
by: Kazuhisa Hagiwara, et al.
Published: (2016-01-01)

Two-year follow up of silodosin on lower urinary tract functions and symptoms in patients with benign prostatic hyperplasia based on prostate size: a prospective investigation using urodynamics
by: Yoshihisa Matsukawa, et al.
Published: (2018-09-01)

Novel Treatments for Men with Lower Urinary Tract Symptoms Suggestive of Benign Prostate Hyperplasia
by: Shiu-Dong Chung, et al.
Published: (2009-05-01)

P1.14 PWV IMPROVEMENT IN PREVIOUSLY UNTREATED MILD HYPERTENSIVE PATIENTS AFTER 1 YEAR OF MONOTHERAPY
by: E. Rodilla, et al.
Published: (2014-11-01)

Evaluation of static and dynamic Pupillometry changes in men using Silodosin for benign prostatic hypertrophy
by: Umut Karaca, et al.
Published: (2021-03-01)

Monotherapy versus combination therapy in the treatment of benign prostatic hyperplasia: A single center study
by: Wishyar Jamal Al-Bazzaz, et al.
Published: (2020-12-01)

Economic Evaluation of Combination Therapy Versus Monotherapy for Treatment of Benign Prostatic Hyperplasia in Hong Kong
by: David Bin-Chia Wu, et al.
Published: (2018-10-01)

Short-term effect of tamsulosin and finasteride monotherapy and their combination on nigerian men with benign prostatic hyperplasia
by: Benjamin O Odusanya, et al.
Published: (2017-01-01)

Effect of Silodosin, an Alpha1A-Adrenoceptor Antagonist, on Ventral Prostatic Hyperplasia in the Spontaneously Hypertensive Rat.
by: Shogo Shimizu, et al.
Published: (2015-01-01)

The Add-On Effect of Solifenacin for Patients with Remaining Overactive Bladder after Treatment with Tamsulosin for Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction
by: Naoya Masumori, et al.
Published: (2010-01-01)

EFFECTIVENESS AND SAFETY OF THE «DE ALEX» BIO COMPLEX AS MONOTHERAPY AND IN COMBINATION WITH TAMSULOSIN IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA
by: P. A. Scheplev, et al.
Published: (2017-11-01)

Prostatic anatomical parameters correlate with clinical characteristics suggestive of benign prostatic hyperplasia
by: Ye Tian, et al.
Published: (2021-01-01)

Precision medicine in the diagnosis and treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia
by: Jing-Liang Chen, et al.
Published: (2020-01-01)

Management of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia by general practitioners in Jakarta
by: Faisal Abdi Matondang, et al.
Published: (2014-06-01)

Comparison of transurethral incision of the prostate and silodosin in patients having benign prostatic obstruction in terms of retrograde ejaculation
by: Basri Cakiroglu, et al.
Published: (2017-03-01)

Efficacy and safety of 5 alpha-reductase inhibitor monotherapy in patients with benign prostatic hyperplasia: A meta-analysis.
by: Jae Heon Kim, et al.
Published: (2018-01-01)

Impacts of medical treatments for lower urinary tract symptoms suggestive to benign prostatic hyperplasia on male sexual functions
by: Shih-Tsung Huang
Published: (2016-03-01)

The Effect of Seoritae Extract in Men with Mild to Moderate Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia
by: Woong Jin Bae, et al.
Published: (2016-01-01)

Focus on Silodosin: Pros and Cons of Uroselectivity
by: Califano G, et al.
Published: (2020-12-01)

A randomized clinical trial to evaluate efficacy and safety of monotherapy with tadalafil or tamsulosin and their combination in men with benign prostatic hyperplasia
by: M. Bibi, et al.
Published: (2020-07-01)

Meta-analysis of the efficacy and safety of combination of tamsulosin plus dutasteride compared with tamsulosin monotherapy in treating benign prostatic hyperplasia
by: Zhongbao Zhou, et al.
Published: (2019-03-01)

Benign Prostatic Hyperplasia
Published: (2015-01-01)

Benign prostatic hyperplasia
by: Ricardo L. V. Nunes, et al.

The global burden of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A systematic review and meta-analysis
by: Shaun Wen Huey Lee, et al.
Published: (2017-08-01)

Personalized therapeutics of α1-blockers in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia
by: Zhu LL, et al.
Published: (2015-03-01)

Relation of baseline prostate volume to improvement of lower urinary tract symptoms due to tamsulosin monotherapy in benign prostatic hyperplasia: An exploratory, multicenter, prospective study
by: Mahmoud Shoukry El-Adawy, et al.
Published: (2020-01-01)

Comparative efficacy and safety profile of 4 vs 8 mg of silodosin once daily usage in patients with benign prostatic hyperplasia–related lower urinary tract symptoms divided into subgroups according to International Prostate Symptom Score severity
by: Abdullah Gul, et al.
Published: (2020-12-01)

Maculopapular type drug eruption caused by silodosin
by: Akiha Inoue, et al.
Published: (2016-04-01)

Silodosin-associated intraoperative floppy iris syndrome
by: Samrat Chatterjee, et al.
Published: (2017-01-01)

Efficacy and safety of Finasteride (5 alpha-reductase inhibitor) monotherapy in patients with benign prostatic hyperplasia: A critical review of the literature
by: Gian Maria Busetto, et al.
Published: (2020-01-01)

Cannot write session to /tmp/vufind_sessions/sess_0ejnqdb6pp5nm46qu13deda5jk